Alterations in genes of the EGFR signaling pathway and their relationship to EGFR tyrosine kinase inhibitor sensitivity in lung cancer cell lines. - Test2 - elhamkhani - TriplyDB

Alterations in genes of the EGFR signaling pathway and their relationship to EGFR tyrosine kinase inhibitor sensitivity in lung cancer cell lines.

Alterations in genes of the EGFR signaling pathway and their relationship to EGFR tyrosine kinase inhibitor sensitivity in lung cancer cell lines.

http://www.wikidata.org/entity/Q33411775

about

From Mice to Men and Back: An Assessment of Preclinical Model Systems for the Study of Lung Cancers Is there a role for epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor wild-type non-small cell lung cancer?Clinical implementation of comprehensive strategies to characterize cancer genomes: opportunities and challenges Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer.Quantitative and sensitive detection of rare mutations using droplet-based microfluidics KRAS mutant allele-specific imbalance in lung adenocarcinoma Mutant allele-specific imbalance modulates prognostic impact of KRAS mutations in colorectal adenocarcinoma and is associated with worse overall survival KRAS mutant allele-specific imbalance is associated with worse prognosis in pancreatic cancer and progression to undifferentiated carcinoma of the pancreas Hereditary lung cancer syndrome targets never smokers with germline EGFR gene T790M mutations Pharmacogenomic discovery using cell-based models Molecular mode of action and role of TP53 in the sensitivity to the novel epothilone sagopilone (ZK-EPO) in A549 non-small cell lung cancer cells Antitumor activity of sorafenib in human cancer cell lines with acquired resistance to EGFR and VEGFR tyrosine kinase inhibitors Modeling of tumor progression in NSCLC and intrinsic resistance to TKI in loss of PTEN expression Contribution of EGFR and ErbB-3 Heterodimerization to the EGFR Mutation-Induced Gefitinib- and Erlotinib-Resistance in Non-Small-Cell Lung Carcinoma Treatments TAE226, a Bis-Anilino Pyrimidine Compound, Inhibits the EGFR-Mutant Kinase Including T790M Mutant to Show Anti-Tumor Effect on EGFR-Mutant Non-Small Cell Lung Cancer Cells In Vitro Drug Sensitivity Tests to Predict Molecular Target Drug Responses in Surgically Resected Lung Cancer A graph theoretic approach to utilizing protein structure to identify non-random somatic mutations.Utilizing protein structure to identify non-random somatic mutations.Copy number amplification of the PIK3CA gene is associated with poor prognosis in non-lymph node metastatic head and neck squamous cell carcinoma.Oncogene mutations, copy number gains and mutant allele specific imbalance (MASI) frequently occur together in tumor cells.In silico insight into EGFR treatment in patients with lung carcinoma and T790M mutations A chemical and phosphoproteomic characterization of dasatinib action in lung cancer Nullifying the CDKN2AB locus promotes mutant K-ras lung tumorigenesis.Erlotinib at a dose of 25 mg daily for non-small cell lung cancers with EGFR mutations.Steroid receptor coactivator-3 expression in lung cancer and its role in the regulation of cancer cell survival and proliferation TGF-beta IL-6 axis mediates selective and adaptive mechanisms of resistance to molecular targeted therapy in lung cancer Lung cancer cell lines as tools for biomedical discovery and research The detection of chromosomal aneusomy by fluorescence in situ hybridization in sputum predicts lung cancer incidence.Should we continue to use the term non-small-cell lung cancer?Signaling networks associated with AKT activation in non-small cell lung cancer (NSCLC): new insights on the role of phosphatydil-inositol-3 kinase.Lung cancer in never smokers: molecular profiles and therapeutic implications.Using iTRAQ combined with tandem affinity purification to enhance low-abundance proteins associated with somatically mutated EGFR core complexes in lung cancer.Mass spectrometry mapping of epidermal growth factor receptor phosphorylation related to oncogenic mutations and tyrosine kinase inhibitor sensitivity.A platform for rapid detection of multiple oncogenic mutations with relevance to targeted therapy in non-small-cell lung cancer Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer.Determination of EGFR mutations in single cells microdissected from enriched lung tumor cells in peripheral blood.Lung cancer cell lines: Useless artifacts or invaluable tools for medical science?Pyrosequencing, a method approved to detect the two major EGFR mutations for anti EGFR therapy in NSCLC.Insights into ALK-driven cancers revealed through development of novel ALK tyrosine kinase inhibitors.Multiplex mutation screening by mass spectrometry evaluation of 820 cases from a personalized cancer medicine registry

P2860

Q26771375-FC1DA5DF-E8CE-4454-9DEB-23AB7A029B1E Q26798882-03A6FDCA-529D-457D-B0E3-5574AD77425E Q26823978-268D1362-6A3B-45D8-9505-0E234C44AD43 Q27851702-53BD185E-A2F0-424A-BD25-0F7689BEB1F8 Q28238121-5B56F6B1-2619-41F2-9BC6-31A2A68910CA Q28242884-6EECE7FD-29D4-4EEA-BAF7-A2B0DB29C793 Q28258483-37AF7CB6-1719-49E1-9C6E-C8DED1FE7049 Q28289209-DAEB908E-522B-4437-B0C3-81DD3804F5FF Q28384015-2738581F-C65C-4194-B90C-FDE8B1CDBE5D Q28392982-3D1A29CF-55A5-4A45-92B4-EA25B9EF0829 Q28477992-6DEC5B12-6FE3-4E40-A312-4EB06EB53CA6 Q28478344-8E6D4D6E-4224-4579-8A7D-21D81C751CF1 Q28484612-70056E59-42AE-467B-AA7B-EB874ECD1D9A Q28547357-2E51C12D-A40A-4887-86D0-C83D2BA8A973 Q28548485-0D66E84F-E614-4292-86A1-4D1BB33D9584 Q28551308-BE76F221-3DBD-4D11-8CEA-8A87F98EEA8E Q30360645-3F59D417-A718-420D-9187-0B6EA5E24D65 Q30431811-EF6A167D-4B8E-4A3D-BA25-98123F38240B Q31096247-D653E44C-4ABB-42DE-874B-0FB777CBB0B1 Q33510334-D8CBF661-ACAF-4921-A877-6702F242DEE3 Q33724006-637E6B30-74C8-451B-9A11-2A88662F0E51 Q33742159-337A0511-E3F1-4D48-AA24-05474E4139D7 Q33758232-1762F628-9907-47BC-A6A6-A3DFB2FEC222 Q33945734-C1672164-C4F6-4B4E-8101-32A0B9E183D4 Q34069119-F6E92D50-686A-4250-81A0-5A79C0E36B29 Q34100276-15C72364-7554-4D4D-A23C-24B8D3B32E52 Q34110617-8215C56E-E553-4399-A2B6-EA94743A287A Q34129229-BFD0F49C-BB45-47DC-BEEB-B2756DCDE3AD Q34143340-6F54A922-12AF-428A-88E1-5D01EABF1EE4 Q34170007-0F49FCCC-09DE-4577-97E6-DADACFB41C5A Q34177155-B5A4BDB3-5AEB-4A69-A09F-8D60A1D6BA19 Q34474427-DD59D650-637B-4480-BB9C-2D3C748625CB Q34631999-A0E2004F-7162-430C-AE0C-6E48A1356A23 Q34760642-83C14351-C387-45BB-A1E2-05BAB5B2A871 Q34773458-D81D750A-AD8A-4C69-9E6E-2673CE420E74 Q34799198-A581E258-E561-4FC3-885D-690740B6710D Q35033316-DEF57CD8-316C-479A-A6B1-BF38203E88E5 Q35061287-ACCFBD3E-4A36-4D75-8398-D9C1703B3B4D Q35112834-CEA39512-B12D-4606-98CD-0EB03A786482 Q35169273-504481DE-67AA-4AD5-8BBE-5384A18BDFF7

P2860

Alterations in genes of the EGFR signaling pathway and their relationship to EGFR tyrosine kinase inhibitor sensitivity in lung cancer cell lines.

http://www.wikidata.org/entity/Q33411775

description

2009 nî lūn-bûn

@nan

2009 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Alterations in genes of the EG ...... ity in lung cancer cell lines.

@ast

Alterations in genes of the EG ...... ity in lung cancer cell lines.

@en

type

label

Alterations in genes of the EG ...... ity in lung cancer cell lines.

@ast

Alterations in genes of the EG ...... ity in lung cancer cell lines.

@en

prefLabel

Alterations in genes of the EG ...... ity in lung cancer cell lines.

@ast

Alterations in genes of the EG ...... ity in lung cancer cell lines.

@en

P1433

Q33411775-AB6F7258-DF6F-4C1F-B0D0-0175B6CC6576

P1476

Q33411775-F8B39F83-BDA2-4BA2-80D3-DDDAE91A84EE

P2093

Q33411775-16AF929C-EAA0-4DE3-8F78-1695E1FFC765

Q33411775-36745327-E95D-46F8-A7FC-4773C46478F2

Q33411775-3AD617BB-9097-4E37-8F01-BEDBA9873108

Q33411775-47BB64B7-8616-468E-909B-AED8A6981AE6

Q33411775-4D659CC1-89F3-414D-8B17-9703B4E82C35

Q33411775-7C62E7B7-9D32-425E-AFD6-4DA7C7160FA5

Q33411775-84F38B2C-6DE5-4B1D-A639-BB64A3D50D52

Q33411775-9ECCAA85-37BF-4A41-8D16-3D16A5335BA2

Q33411775-B9FE06A5-5817-41DC-82C2-1686357E2F71

Q33411775-C694F678-D1E8-49AC-AF0B-10442E993A06

P2860

Q33411775-0A2F03D5-976F-43CB-8986-A2B6CDA51601

Q33411775-1207B7F8-F79D-47DA-A7F8-212973924F41

Q33411775-1245A45B-4D61-4F6C-9B84-F5D4F7A5A7F8

Q33411775-13FB7A18-BEBE-4C11-93AE-52ADB38720A9

Q33411775-19F777AA-836C-47B1-8F55-78533726C91C

Q33411775-21244167-D3C8-4F22-9DF0-DC2EF320CCA4

Q33411775-26CED4DD-B043-44BA-AC99-7C1ED1186D5D

Q33411775-26D01009-C6F7-498D-A0A6-A610FAE3DB52

Q33411775-2A6A5229-9100-4F98-BE26-34775273E16D

Q33411775-2BB77299-482B-4831-9BCC-A512A74E0041

P304

Q33411775-C36D27C4-8CC0-4938-B1CD-38B63D40CE91

P31

Q33411775-92D490BF-CA48-4079-B379-3A4ACB5E8DB4

P356

Q33411775-8524B06D-70E5-4C93-9151-6BAE028BAE40

P407

Q33411775-DDF1D22E-33B8-470C-819C-6099A6195CDF

P433

Q33411775-DEDE9DDD-05A6-4DA4-89B6-0195A94AB790

P478

Q33411775-7FE968B8-EE0D-4596-A1B8-47A1E4A9A974

P577

Q33411775-5813731D-068A-4D5E-999C-38463227CBC8

P5875

Q33411775-9A43593D-96B9-4D1B-822D-01B3CD84A62D

P698

Q33411775-71646247-654D-44E7-94AD-DE0B9233C217

P932

Q33411775-30C00183-C09F-4073-90A7-94A018639169

P356

JOURNAL.PONE.0004576

P1433

P1476

Alterations in genes of the EG ...... ity in lung cancer cell lines.

@en

P2093

Adi F Gazdar

http://www.w3.org/2001/XMLSchema#string

Hiromasa Yamamoto

http://www.w3.org/2001/XMLSchema#string

Hisayuki Shigematsu

http://www.w3.org/2001/XMLSchema#string

Jeet Gandhi

http://www.w3.org/2001/XMLSchema#string

Jianling Zhang

http://www.w3.org/2001/XMLSchema#string

John D Minna

http://www.w3.org/2001/XMLSchema#string

Junichi Soh

http://www.w3.org/2001/XMLSchema#string

Luc Girard

http://www.w3.org/2001/XMLSchema#string

Marileila Varella-Garcia

http://www.w3.org/2001/XMLSchema#string

Michael Peyton

http://www.w3.org/2001/XMLSchema#string

P2860

KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

Intratumoral epiregulin is a marker of advanced disease in non-small cell lung cancer patients and confers invasive properties on EGFR-mutant cells

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

Cancer statistics, 2008

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

High frequency of mutations of the PIK3CA gene in human cancers

Polymorphisms, mutations, and amplification of the EGFR gene in non-small cell lung cancers

Erlotinib in previously treated non-small-cell lung cancer

Lung cancer in never smokers--a different disease

P304

e4576

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0004576

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

4

http://www.w3.org/2001/XMLSchema#string

P577

2009-02-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

24035844

http://www.w3.org/2001/XMLSchema#string

P698

19238210

http://www.w3.org/2001/XMLSchema#string

P932

2642732

http://www.w3.org/2001/XMLSchema#string